We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Saliva Testing for COVID-19 Quicker, Safer than Nasal Swabs

By LabMedica International staff writers
Posted on 23 Mar 2022
Print article
Image: New research supports use of saliva in large-scale screening (Photo courtesy of Pexels)
Image: New research supports use of saliva in large-scale screening (Photo courtesy of Pexels)

Early in the COVID-19 pandemic, the urgent need to increase testing was accompanied by a shortage of supplies, notably nasal swabs, which were then the standard method for collecting samples for testing. Research conducted in order to come up with a solution to this problem has now found that genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs.

To identify people with COVID-19, investigators at the University of Maryland (College Park, MD, USA) began conducting weekly tests of saliva samples from healthy community volunteers in May 2020 and continued over the next two years. Of the asymptomatic volunteers who tested positive, the researchers found that those patients would typically show symptoms a day or two later, making them wonder if saliva was better at catching pre-symptomatic patients than traditional nasal swabs.

To answer that question, the researchers used data from a companion study of close contacts of people with confirmed cases of COVID-19. In the study, the team collected saliva and mid-turbinate nasal swab samples from contacts every two or three days during their quarantine period. All the samples were tested using real-time reverse transcription polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 and measure how much viral RNA was in the samples. The researchers then analyzed how these results changed in the days before and after symptom onset. The findings revealed that early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs, notably so before the onset of symptoms. The study also noted that previous studies had shown that pre-symptomatic transmission plays a greater role than symptomatic transmission of SARS-CoV-2.

These findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening and improving the safety of healthcare workers who conduct testing. In the latter case, saliva self-testing avoids the close contact between patient and healthcare worker that nasal swabbing entails and avoids causing patients to cough and sneeze, thereby spreading virus particles as a result of swabbing the sensitive nasal passages, as well as discomfort to patients.

“Our research supports the use of saliva in large-scale screening in schools and workplaces, as a means of improving screening rates, as well as early detection,” said coauthor Donald K. Milton, M.D., DrPH, a professor of occupational and environmental health at the Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park. “We expect that if rapid saliva tests become available, they could be a major advance from the current nasal swab-based rapid tests.”

Related Links:
University of Maryland 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.